he isoprenoid biosynthesis pathways produce the largest class of small molecules in Nature: isoprenoids (also called terpenoids). Not surprisingly then, isoprenoid biosynthesis is a target for drug discovery, and many drugsssuch as Lipitor (used to lower cholesterol), Fosamax (used to treat osteoporosis), and many anti-infectivesstarget isoprenoid biosynthesis. However, drug resistance in malaria, tuberculosis, and staph infections is rising, cheap and effective drugs for the neglected tropical diseases are lacking, and progress in the development of anticancer drugs is relatively slow. Isoprenoid biosynthesis is thus an attractive target, and in this Account, I describe developments in four areas, using in each case knowledge derived from one area of chemistry to guide the development of inhibitors (or drug leads) in another, seemingly unrelated, area.
Introduction
Isoprenoids represent the largest class of small molecules on earth, 1 Once formed, IPP and DMAPP condense via a "head-to-tail" mechanism to form geranyl diphosphate (5) and farnesyl diphosphate (6) in reactions catalyzed by the enzyme farnesyl diphosphate synthase (FPPS), and further reaction with IPP catalyzed by the enzyme geranylgeranyl diphosphate synthase (GGPPS) yields the C 20 species, geranylgeranyl diphosphate (GGPP, 7), 6, 7 Scheme 2.
Both FPP and GGPP are used in protein prenylation (of importance in cell survival and signaling pathways), and FPP can also condense in a "head-to-head" manner via presqualene diphosphate (PSPP, 8) 8 to form triterpenes, Scheme 3. In humans, this condensation is accompanied by an NADPH reduction step and results in formation of squalene (9) , 9 but in the bacterium S. aureus, the reduction step is missing and the enzyme CrtM converts FPP to dehydrosqualene (10) . 10 In many organisms, squalene is epoxidized to form oxidosqualene (11) , which is then cyclized to form lanosterol (12) , which after several additional steps, is transformed into cholesterol (13) in humans or ergosterol (14) or episterol (15) in yeasts, fungi, and parasitic protozoa. In S. aureus, 10 is also converted to a carotenoid pigment, staphyloxanthin (16), 10 an important virulence factor. The enzymes involved in these reactions are our targets, and I describe here our progress in understanding their structures, mechanisms of action, and inhibition, focusing on the use of a less-conventional, knowledge-based approach to inhibitor or drug discovery.
IspH (LytB), an Fe 4 S 4 -Cluster-Containing Enzyme
The IspH enzyme is found in the vast majority of pathogenic bacteria, 11 as well as in malaria parasites, 12 and since it is not found in humans and is essential for pathogen survival, it is an important target for anti-infective development. Working with Jomaa and Ermler, we reported 13 that the enzyme has a unique, trefoil-like structure, Figure 1A ,B, with a central Fe 3 S 4 cluster, and a similar structure was then reported by Grawert et al. 14 The observation that both proteins contained 3Fe and not 4Fe was inconsistent with the results of electron paramagnetic resonance (EPR), 5 chemical analysis, 5, 15 and activity 5, 15 results, which all pointed to an Fe 4 S 4 cluster, so we next used computational methods to construct an Fe 4 S 4 model, with the HMBPP substrate docking to the unique fourth Fe in oxidized IspH, via its 1-OH group, initially as an alkoxide, 13 Figure 1C .
Interestingly, very recent X-ray crystallographic results 16 have shown that HMBPP does in fact bind to the 4Fe cluster SCHEME 14 and we reasoned that by using an inactive IspH mutant (E126A), it might be possible to "trap" a reaction intermediate, which would give clues as to the catalytic mechanism, if its structure could be deduced. To do this, we used EPR and electron-nuclear double resonance (ENDOR) spectroscopy. 17 Simply adding HMBPP to reduced IspH yielded an EPR spectrum that was essentially the same as that obtained on adding the IPP product ( Figure 2A ). However, the EPR spectrum obtained when using the E126A mutant was very differ- similarities to the EPR spectra of the HMBPP "parent" molecules, ethylene (17) and allyl alcohol (18) , when bound to a nitrogenase FeMO cofactor. 18, 19 In nitrogenase, the results of both ENDOR 18, 19 and DFT cal- can form, Figure 3 . On reduction and protonation at C2, the IPP product forms, while protonation at C4 would form DMAPP, Figure 3A ,B, an organometallic as opposed to a purely radical mechanism for catalysis. 17 These spectroscopic results suggest the likely importance of organometallic intermediates in IspH catalysis, which leads to a new idea for inhibitor design, based on organometallic precedent. In previous work, several groups reported that alkynes could be cis-reduced by "model" Fe 4 Figure 4A ) exhibited large hyperfine couplings (∼6 MHz for 13 C, ∼10 MHz for 1 H). 17 Compound 26 was also a K i ≈ 970 nM IspH inhibitor ( Figure 4B ), ∼1000× more active than previously reported inhibitors. 23 A likely explanation of this good inhibition is formation of the π/σ metallacycle 27, in which the alkyne can bind to the unique fourth Fe, Figure 4C , opening up, potentially, a new route to anti-infective development.
FPPS (and GGPPS): Structure, Mechanism, and Inhibition by Lipophilic Bisphosphonates
The IPP and DMAPP produced by either the nonmevalonate or mevalonate pathways are next condensed by FPPS and GGPPS to form FPP and GGPP, Scheme 2. FPPS is the target of the bisphosphonate class of drugs used to treat bone resorption diseases, but for many years, their mechanism of action was unknown. Our interest in these systems arose from several chance observations. First, working with Urbina and Docampo, we found 24 that Trypanosoma cruzi contained very high levels of condensed phosphates, such as diphosphate 28, Scheme 6. This led to the idea that nonhydrolyzable PPi analogs, bisphosphonates such as pamidronate (29) and risedronate (30, Actonel), might inhibit parasite cell growth. This turned out to be the case, 24, 25 but the target was not known!
The second chance observation was that we noticed that nitrogen-containing analogs of GPP such as 31, known to be potent, low nanomolar inhibitors of terpene cyclases, looked 
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suspiciously like the bisphosphonate ibandronate, 32, as did their electrostatic potential surfaces, Φ(r), Figure 5A ,B. 26 This suggested that cationic bisphosphonates might act as carbocation/diphosphate isosteres, inhibiting isoprenoid biosynthesis, a view supported by the observation that bisphosphonates were reported to act in the mevalonate pathway. 27 The third observation was that bisphosphonates such as 33 had been developed by Zeneca as herbicides 28 and had been shown to be low nanomolar inhibitors of a daffodil FPPS. 28 Since we noticed that 33 had also been shown 29 to be active in bone resorption, we proposed 26 that the bone-resorption drugs might act by inhibiting FPPS, mimicking a carbocation reactive intermediate (34) , Scheme 7, docking into the allylic site in FPPS, Figure 5C . 26 The FPPS target was soon confirmed, [30] [31] [32] and the allylic binding mode that we proposed was later confirmed crystallographically by Hosfield et al. 33 ( Figure 5D ). In later work, we also showed that pamidronate provided a parasitological cure of cutaneous leishmaniasis in mice, Figure 6A ,B, 34 by blocking FPPS and, thus, ergosterol biosynthesis, 25 opening up the possibility of the clinical use of bisphosphonates as anti-infectives. 35 In addition to their activity as bone resorption drugs and antiparasitics, bisphosphonates kill tumor cells, 36 removing the 1-OH group would reduce bone-binding, and adding more hydrophobic substituents would enhance cell or tissue penetration, so that species such as BPH-715 (36) would be more potent inhibitors of tumor cell growth.
This turned out to be the case, 42 with 36 killing tumor cell lines with an IC 50 of ∼100 nM, at least 100× lower than that found with the bisphosphonate zoledronate (35). Compound 36 also blocked tumor cell invasion, 42 and it was a potent activator of γδ T cells, 43 in addition to having good activity, in vivo. 42 The enhanced activity of 36 is likely due to several factors. First, it inhibits FPPS, 42 which results in blocking protein (e.g., K-ras) prenylation. Second, since it is lipophilic, it gets into cells more readily than do more polar analogs. Third, when FPPS is inhibited, the substrates IPP and DMAPP build up, and these are converted to toxic ATP analogs 44 such as ApppI (37) . 44 Fourth, the buildup of IPP (and DMAPP) in tumor cells on FPPS inhibition leads to activation of γδ T cells, since both IPP and DMAPP are so-called "phosphoantigens". 45 Fifth, lipophilic bisphosphonates inhibit GGPPS by docking into the product binding site ( Figure 5E ), 42, 46 and the combined effects of FPPS and GGPPS inhibition are likely synergistic (preventing cross-prenylation). When combined with poor bone-binding, this leads to potent in vivo activity.
Dehydrosqualene Synthase (CrtM) and Staphyloxanthin: An Anti-Virulence Approach to Staph Infections
In humans, most FPP is converted via the "head-to-head" triterpene synthase, squalene synthase (SQS), to squalene 9. While involved in some "recreational" reading, I noticed an Figure 7A ), and using a nonreactive, sulfur-containing analog of FPP, S-thiolo-FSPP (38), Scheme 8, we found two "FPP" binding sites, as hoped ( Figure 7B ). We then synthesized a range of potential CrtM inhibitors, compounds that had all been developed as SQS inhibitors, and tested them for CrtM inhibition. The most potent inhibitors were bisphosphonates such as 39. However, they did not block staphyloxanthin (16) formation in cells. On the other hand, phosphonosulfonates (40) and phosphonoacetamides (41) inhibited both CrtM activity in vitro and staphyloxanthin biosynthesis in S. aureus, with the crystallographic results showing that they bound to one or the other FPP sites, Figure 7C . 49 When S. aureus is stripped of its protective carotenoid shield, cells grow normally in vitro since virulence factors are not essential for cell growth. However, the cells are white ( Figure 8A) , and when the cells are exposed to reactive oxygen species, either from H 2 O 2 or by adding neutrophils, cell growth is greatly inhibited (Figures  8B) . [49] [50] [51] Moreover, in mice ( Figure 8C ), we found a 98% decrease in S. aureus in the kidneys 49 on treatment with 40.
These results are of interest since they represent a potentially new, highly selective approach to blocking staph infections in which cells are made highly susceptible to killing by the host's 
Using the Heart Drug Amiodarone as an Anti-infective against Chagas Disease and Leishmaniasis
After condensing FPP to squalene, humans, plants, fungi, and yeasts, as well as the pathogenic protozoa T. cruzi and Leishmania mexicana, carry out an epoxidation to form oxidosqualene (11), which is then cyclized to form lanosterol (12) . Again while perusing one of the more populist journals, my attention was drawn to an article 53 reporting observations by Courchesne 54 and Gupta et al. 55 that the class III antiarrhythmia drug amiodarone (42), Scheme 9, had unexpected activity against baker's yeast. An effect on Ca 2+ channels was
shown, but what was more surprising was that cell growth inhibition activity was synergistic with the azole antibiotics that are commonly used to treat yeast or fungal infections, drugs such as such as fluconazole (43) . It seemed likely to me that ergosterol biosynthesis might be involved. I e-mailed Urbina to see whether we should try amiodarone in T. cruzi. His There was then an apparent lull in activity, but in very recent work, Serrano-Martin et al. 57 have reported that 58 have begun to report the results of small clinical trials of amiodarone (with and without itraconazole, 46). In one case, a patient had concurrent Chagas disease and cutaneous leishmaniasis. This is a difficult combination to treat since the standard drugs used to treat leishmaniasis are antimonials, which are problematic in patients with cardiac arrythmias (as in Chagas disease). The patient was treated with amiodarone to stabilize the heart condition, but remarkably, the cutaneous lesions also healed, without use of any specific antileishmanial therapy. 58 In a second study, 59 the combination amiodarone and itraconazole was used to treat a Chagas disease patient, with a parasitological cure of the T. cruzi infection being reported. 59 In addition, a 100% cure rate has now been found in 11 patients with cutaneous leishmaniasis. 60 This efficacy is very high and is thought to be due, at least in part, to the very unusual excretion mechanism for amiodarone, through the skin! 61
Concluding Remarks and Perspectives
The results described above give a brief summary of the last 10 years work in our laboratory on isoprenoid biosynthesis enzymes, which has focused on discovering new drug targets, mechanisms, and inhibitors. The results with the Fe 4 S 4 cluster-containing protein IspH seem radical but are simply based on precedent (ethylene, allyl alcohol nitrogenase ENDOR, and DFT) and have led to the first micromolar IspH inhibitors and a new proposal for catalysis, involving organometallic species. With the head-to-tail synthases FPPS (and GGPPS), there are now ∼60 crystallographic structures reported, including some with the novel, lipophilic bisphosphonates, which now await more extensive preclinical testing. With CrtM, we have the first structure of a head-to-head triterpene synthase containing bound substrate analogs, together with novel inhibitors. These block S. aureus proliferation in vivo, and one has already been tested for safety in humans (in the context of its role as a cholesterol-lowering drug). And finally, we discovered another drug "repurposing": the use of the antiarrythmia drug, amiodarone, as an agent against both Chagas disease and cutaneous leishmaniasis. Since Chagas disease affects ∼10 000 000 individuals in South America and there is no cure for the chronic stage of the disease (the leading cause of sudden death on the subcontinent), the combination of amiodarone plus an azole is of considerable interest, as is its use alone in treating some forms of cutaneous leishmaniasis.
In each of the examples described above, we have used a knowledge-based approach, rather than purely screeningbased methods, to find new leads in which we use information from one area of research to suggest drug (or inhibitor) leads in another, seemingly unrelated area. Since terpenes or isoprenoids are the largest class of small molecules known and their biosynthesis is already the target for many current drugs, it seems likely that many new drugs will be found that target their formation, but as Pasteur famously said: "Chance favors only the prepared mind". 
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